Bleselumab
Monoclonal antibody
- none
- 1453067-91-8
- none
- AS3AZ5R46K
- D11357
Bleselumab (INN;[1] development code ASKP1240) is a human monoclonal antibody designed for the prevention of organ transplant rejection.[2][3]
This drug was developed by Kyowa Kirin Pharmaceutical Development Inc.[4]
References
- ^ World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 113" (PDF). WHO Drug Information. 29 (2).
- ^ Wojciechowski D, Vincenti F (November 2016). "Current status of costimulatory blockade in renal transplantation". Current Opinion in Nephrology and Hypertension. 25 (6): 583–590. doi:10.1097/MNH.0000000000000268. PMID 27517137. S2CID 4379881.
- ^ Malvezzi P, Jouve T, Rostaing L (November 2016). "Costimulation Blockade in Kidney Transplantation: An Update". Transplantation. 100 (11): 2315–2323. doi:10.1097/TP.0000000000001344. PMC 5084636. PMID 27472094.
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Bleselumab, American Medical Association.
- v
- t
- e
Monoclonal antibodies for the immune system
Human | |
---|---|
Humanized | |
Veterinary |
Mouse |
|
---|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e